Lovenox Quest For Fresh Patent Continues; ANDAs May Face “Premarin” Problem
Aventis will continue to pursue a re-issuance of its low weight heparinLovenox patent despite a second rejection by the Patent & Trademark Office
You may also be interested in...
Sandoz' pending NDA for Omnitrope appears ripe for an FDA decision
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011